Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical Allogeneic Peripheral Blood Transplantation
NCT03480360Phase 3Completed
- Sponsor
- Dartmouth Health
- Start
- Mar 2018
- Primary completion
- Feb 2025
- Modality
- Stem Cell Therapies, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML) and 6 more, sponsored by Dartmouth Health. Primary endpoints: Number of Participants Who Survived to 100-Days Post-transplant, Number of Participants Who Survived to One Year Post-Transplant at 1 year and 8 more. Started Mar 2018; status: completed.
02
Conditions
acute myeloid leukemia (AML)chronic lymphocytic leukemia (CLL)chronic myeloid leukemia (CML)myelodysplastic syndromes (MDS)myeloproliferative disorder (MPD)
Beyond the preview
Go deeper on NCT03480360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480360.